SG11202113265PA - Triple pharmaceutical composition for proteinaceous infection - Google Patents
Triple pharmaceutical composition for proteinaceous infectionInfo
- Publication number
- SG11202113265PA SG11202113265PA SG11202113265PA SG11202113265PA SG11202113265PA SG 11202113265P A SG11202113265P A SG 11202113265PA SG 11202113265P A SG11202113265P A SG 11202113265PA SG 11202113265P A SG11202113265P A SG 11202113265PA SG 11202113265P A SG11202113265P A SG 11202113265PA
- Authority
- SG
- Singapore
- Prior art keywords
- proteinaceous
- infection
- pharmaceutical composition
- triple
- triple pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962861855P | 2019-06-14 | 2019-06-14 | |
| US16/504,723 US20200000829A1 (en) | 2018-06-27 | 2019-07-08 | Therapy and prevention of prion protein complex infections |
| US16/565,242 US10729705B2 (en) | 2018-06-27 | 2019-09-09 | Therapy and prevention of prion protein complex infections in non-human animals |
| PCT/US2020/037787 WO2020252475A1 (en) | 2019-06-14 | 2020-06-15 | Triple pharmaceutical composition for proteinaceous infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202113265PA true SG11202113265PA (en) | 2021-12-30 |
Family
ID=73782140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202113265PA SG11202113265PA (en) | 2019-06-14 | 2020-06-15 | Triple pharmaceutical composition for proteinaceous infection |
Country Status (8)
| Country | Link |
|---|---|
| JP (1) | JP2022537132A (en) |
| KR (1) | KR20220020832A (en) |
| CN (1) | CN114007609A (en) |
| BR (1) | BR112021025253A2 (en) |
| CA (1) | CA3142164A1 (en) |
| MX (1) | MX2021015266A (en) |
| SG (1) | SG11202113265PA (en) |
| WO (1) | WO2020252475A1 (en) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7189703B2 (en) * | 1998-01-09 | 2007-03-13 | Intracell, Llc | Treatment and diagnosis of alzheimer's disease |
| JP2006502188A (en) * | 2002-09-17 | 2006-01-19 | ニューヨーク ユニバーシティ | Methods for treating age-related memory deficits (AAMI), moderate cognitive deficits (MCI), and dementia with cell cycle inhibitors |
| WO2005099823A1 (en) * | 2004-04-14 | 2005-10-27 | Warner-Lambert Company Llc | Therapeutic combination for treatment of alzheimers disease |
| US20140271923A1 (en) * | 2013-03-14 | 2014-09-18 | Christopher Brian Reid | Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions |
| WO2015037023A1 (en) * | 2014-08-18 | 2015-03-19 | Silvestri Fabrizio De | Use in one pill / tablet / capsule minocycline, acicloguanosin, atorvastatin and vitamin d in the treatment of rheumatoid arthritis |
| DE102016208567A1 (en) * | 2016-05-19 | 2017-11-23 | Heraeus Medical Gmbh | Polymer solution for viscous supplementation |
| US10350226B1 (en) * | 2018-06-27 | 2019-07-16 | Joshua O. Atiba | Therapy and prevention of prion protein complex infections |
-
2020
- 2020-06-15 BR BR112021025253A patent/BR112021025253A2/en unknown
- 2020-06-15 SG SG11202113265PA patent/SG11202113265PA/en unknown
- 2020-06-15 WO PCT/US2020/037787 patent/WO2020252475A1/en active Application Filing
- 2020-06-15 CN CN202080042131.XA patent/CN114007609A/en active Pending
- 2020-06-15 KR KR1020217041835A patent/KR20220020832A/en unknown
- 2020-06-15 CA CA3142164A patent/CA3142164A1/en active Pending
- 2020-06-15 JP JP2021573291A patent/JP2022537132A/en active Pending
- 2020-06-15 MX MX2021015266A patent/MX2021015266A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3982956A1 (en) | 2022-04-20 |
| MX2021015266A (en) | 2022-01-18 |
| BR112021025253A2 (en) | 2022-04-12 |
| CA3142164A1 (en) | 2020-12-17 |
| KR20220020832A (en) | 2022-02-21 |
| CN114007609A (en) | 2022-02-01 |
| WO2020252475A1 (en) | 2020-12-17 |
| EP3982956A4 (en) | 2023-05-03 |
| JP2022537132A (en) | 2022-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3817722A4 (en) | Pharmaceutical compositions comprising meloxicam | |
| EP4045480A4 (en) | Pharmaceutical formulations | |
| GB202008961D0 (en) | Pharmaceutical composition | |
| EP3946316A4 (en) | Cannabidiol pharmaceutical compositions | |
| GB201911517D0 (en) | Pharmaceutical composition | |
| EP3868371A4 (en) | Novel pharmaceutical composition | |
| IL290469A (en) | Oral pharmaceutical composition | |
| EP3881841A4 (en) | Pharmaceutical composition | |
| EP3984549A4 (en) | Medicinal composition | |
| SG11202113265PA (en) | Triple pharmaceutical composition for proteinaceous infection | |
| EP3949952A4 (en) | Medicinal composition | |
| EP3914234A4 (en) | Pharmaceutical compositions | |
| EP3964264A4 (en) | Novel pharmaceutical composition | |
| EP3950058A4 (en) | Pharmaceutical composition having favorable stability | |
| EP4011393A4 (en) | Pharmaceutical agent for transmucosal administration | |
| EP4081251A4 (en) | Pharmaceutical compositions | |
| EP3920909A4 (en) | Pharmaceutical compositions comprising meloxicam | |
| EP3845230A4 (en) | Pharmaceutical composition for oral administration | |
| FI3908321T3 (en) | Pharmaceutical composition | |
| EP3806838A4 (en) | Pharmaceutical compositions comprising poh derivatives | |
| EP3841108A4 (en) | Pharmaceutical compositions comprising integration-promoting peptides | |
| EP3746080A4 (en) | Pharmaceutical formulations | |
| EP4032535A4 (en) | Pharmaceutical composition | |
| EP3991750A4 (en) | Pharmaceutical composition | |
| EP3957318A4 (en) | Pharmaceutical composition |